Influence of Valve Type and Antiplatelet Regimen on Platelet Reactivity After TAVI: Subanalysis of the REAC-TAVI Trial.
Blanca Trejo-Velasco, Ignacio Cruz-González, Antonio Tello-Montoliu...
https://pubmed.ncbi.nlm.nih.gov/32771996/Actively Recruiting
Led by Fundacin Biomedica Galicia Sur · Updated on 2026-07-28
1206
Participants Needed
1
Research Sites
52 weeks
Total Duration
Researchers are studying the best medication to use after transcatheter aortic valve implantation TAVI to prevent valve blood clots and reduce complications like stroke without causing too much bleeding. This trial compares two single antiplatelet therapies, Aspirin and Ticagrelor, to find the most suitable option, especially for patients who have other chronic conditions like coronary artery disease, diabetes, or peripheral vascular disease. These conditions raise the risk of complications after TAVI, making this research important for improving patient care. Participants will receive either Aspirin 100 mg once daily or Ticagrelor 60 mg twice daily after their TAVI procedure. The study randomly assigns patients to one of these two treatments to evaluate and compare their safety and effectiveness. Both treatments aim to reduce the chance of blood clots and thromboembolic events, and the study follows patients for at least 12 months to assess outcomes including valve thrombosis, major bleeding, and other patient-related health events. During the study, participants will be regularly monitored through clinical visits to assess safety and treatment effects. Researchers will measure the occurrence of major adverse cardiac and cerebrovascular events NACE at 12 months as the primary outcome. Secondary assessments include checking for subclinical valve thrombosis at 3 and 12 months, major bleeding events, and composite patient outcomes. Participants must attend follow-up visits to track progress and ensure safety throughout the study period, which may last up to several years.
CONDITIONS
Single Antiplatelet Treatment With Ticagrelor or Aspirin After Transcatheter Aortic Valve Implantation
V
Victor A Jiménez Díaz, MD, MPH
P
Pablo Juan-Salvadores, Pharma, MPH, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Fundacin Biomedica Galicia Sur
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 12 months
Participants receive either Aspirin 100 mg once daily or Ticagrelor 60 mg twice daily after their TAVI procedure.
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Blanca Trejo-Velasco, Ignacio Cruz-González, Antonio Tello-Montoliu...
https://pubmed.ncbi.nlm.nih.gov/32771996/Victor Alfonso Jimenez Diaz, Antonio Tello-Montoliu, Raul Moreno...
https://pubmed.ncbi.nlm.nih.gov/30621974/Victor Alfonso Jimenez Diaz, Iñigo Lozano, Antonio Tello Montoliu...
https://pubmed.ncbi.nlm.nih.gov/31857029/Victor Alfonso Jimenez Diaz, Iñigo Lozano, Jose Antonio Baz Alonso...
https://pubmed.ncbi.nlm.nih.gov/31072513/Victor Alfonso Jimenez Diaz, Antonio Tello-Montoliu, Raul Moreno...
https://pubmed.ncbi.nlm.nih.gov/31000022/Blanca Trejo-Velasco, Antonio Tello-Montoliu, Ignacio Cruz-González...
https://pubmed.ncbi.nlm.nih.gov/34117181/Jorn Brouwer, Vincent J Nijenhuis, Ronak Delewi...
https://pubmed.ncbi.nlm.nih.gov/32865376/Won-Keun Kim, Costanza Pellegrini, Sebastian Ludwig...
https://pubmed.ncbi.nlm.nih.gov/34294400/Victor Alfonso Jimenez Diaz, Jose Antonio Baz Alonso, Oscar Estevez Ojea...
https://pubmed.ncbi.nlm.nih.gov/29908965/Fundacin Biomedica Galicia Sur
Lead Sponsor